Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference
Calgary, AB – TheNewswire – June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO ) , ( OTC:IBOGF ) and ( FSE:JC4) (“ UI ” or the “ Company ”) a life sciences company with a mission to transform addiction treatment using medicalized ibogaine and a global licensing model is pleased to announce that Nick Karos, CEO will present at the H.C. Wainwright 1 st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. The event is a hybrid online and in person event scheduled for June 27, 2022.
About H.C. Wainwright
H.C. Wainwright & Co is one of the oldest and most trusted names in corporate finance in the USA providing investment banking, corporate advisory, research, and analysis covering sectors including Healthcare & Life Sciences, Mining, Cleantech, Shipping & Maritime and Technology.
H.C. Wainwright hosts a robust calendar of conferences and events in the Healthcare sector. More information and registration for the 1 st Annual Mental Health Conference can be found here .
Nick Karos CEO of Universal Ibogaine commented “H.C. Wainwright is a leader in the space and could be a strong strategic partner in our ongoing corporate finance roadmap. The opportunity to tell our story to this audience is another important step in developing the awareness around brand and offering.
Correction Notice June 13 Blue Digital Media
In UI’s June 13, 2022 News Release it was stated that stock options to be granted to investor relations advisory firm Blue Digital Media would vest one-third at the end of each month in the 3 month term of service. Under TSXV Exchange Policy 4.4 Security Based Compensation, stock options for investor relations firms must vest quarterly over a 12 month period with the first vesting for 25% of the options at 3 months,25% at 6 months, 25% at 9 months and the final 25% at 12 months.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ”could” occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations: Dugan Selkirk, Investor Relations Manager
Related Links https://universalibogaine.com